SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-093093
Filing Date
2021-07-16
Accepted
2021-07-16 16:30:31
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2119969d3_defa14a.htm DEFA14A 19938
2 GRAPHIC tm2119969d3_defa14aimg001.jpg GRAPHIC 3466
  Complete submission text file 0001104659-21-093093.txt   25959
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37558 | Film No.: 211095773
SIC: 2834 Pharmaceutical Preparations